Sunil Singhania, Mukul Agrawal, and Vikas Khemani Lead the Charge in India’s Largest SME IPO

India’s largest SME IPO to date, Q-Line Biotech, is making waves in the market by securing INR 61.09 crore from a selection of prominent institutional investors ahead of its IPO of INR 214.48 crore. The anchor book allocation was finalized on May 20, 2026, featuring significant commitments from well-regarded names in Dalal Street, including Abakkus Mutual Fund and Carnelian AIF. This strong institutional backing is vital for retail investors as it serves as an endorsement of the company’s business strategy and operational viability, alleviating potential concerns regarding the SME listing.

Q-Line Biotech allocated 17.81 lakh equity shares at the top price band of INR 343 per share to 18 institutional investors, reflecting a robust demand. The largest share allocation came from Abakkus Small Cap Fund, which secured 2.91 lakh shares, indicating a significant stake in this promising company. Additionally, strong participation from other funds like Carnelian AIF and Sanshi Fund-I further illustrates the bullish sentiment among seasoned institutional investors. Such heightened interest in the anchor round bodes well for the forthcoming public offering, indicating a potentially positive grey market sentiment.

For Indian investors, the launch of Q-Line Biotech’s IPO represents a significant opportunity, particularly in the SME segment, which has traditionally offered limited avenues for retail participation. The strong institutional backing effectively de-risks the investment perception, instilling confidence in the company’s long-term growth potential. As Q-Line Biotech opens its subscription window from May 21 to 25, 2026, this IPO stands to be a critical test for the Indian SME market, signaling a renewed interest and trust in smaller enterprises aiming for growth in a challenging economic landscape.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova IPO team.)